Protalix BioTherapeutics to Hold Fiscal Year 2022 Financial and Business Results Conference Call on February 27, 2023

Protalix BioTherapeutics (NYSE: PLX) will announce its fiscal year 2022 financial results and provide a business update on February 27, 2023.

Rhea-AI Summary

Protalix BioTherapeutics (NYSE: PLX) will announce its fiscal year 2022 financial results and provide a business update on February 27, 2023. The event will include a conference call at 8:30 a.m. EST, where management will discuss the financial outcomes and recent corporate developments. The company's proprietary ProCellEx® system produces therapeutic proteins, with taliglucerase alfa being its first FDA-approved product. Protalix's pipeline includes products targeting key health issues like Fabry disease and severe gout, indicating ongoing investment in innovative biopharmaceuticals.

Positive

• Upcoming conference call to discuss financial results, enhancing transparency with investors.
• Protalix has FDA-approved products, establishing credibility in the biopharmaceutical industry.
• Diverse pipeline targeting major health concerns, indicating potential for future growth.

Negative

• None.

Argus Session date unavailable

+1.92% session move Open Argus

Details

News Market Reaction – PLX

The recorded move for PLX in the trading session of this news was +1.92%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Company to host conference call and webcast at 8:30 a.m. EST.

CARMIEL, Israel, Feb. 21, 2023 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx^® plant cell-based protein expression system, today announced that it will release its financial results for fiscal year 2022 and provide a business update on Monday, February 27, 2023.

 

The Company's Management will host a conference call with investors to discuss the financial results and provide an update on recent corporate and regulatory developments.

Conference Call Details:

Date:                           Monday, February 27, 2023

Time:                           8:30 a.m. Eastern Standard Time (EST)

Toll Free (U.S.):          1-877-423-9813

International:               1-201-689-8573

Conference ID:           13736250

Webcast Details:

The conference will be webcast live from the Company's website and will be available via the following links:

Company Link: https://protalixbiotherapeutics.gcs-web.com/events0

Webcast Link: Registration – https://tinyurl.com/5n6rtnhw

Conference ID: 13736250

Please access the websites at least 15 minutes ahead of the conference to register, download and install any necessary audio software.

The conference call will be available for replay for two weeks on the Events Calendar of the Investors section of the Company's website, at the above link.

About Protalix BioTherapeutics, Inc.

Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx^®. Protalix was the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. Protalix's unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner.

Protalix's first product manufactured by ProCellEx, taliglucerase alfa, was approved by the FDA in May 2012 and, subsequently, by the regulatory authorities of other countries. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights for taliglucerase alfa, excluding Brazil, where Protalix retains full rights.

Protalix's development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: pegunigalsidase alfa, a modified stabilized version of the recombinant human α–Galactosidase–A protein for the treatment of Fabry disease; PRX–115, a plant cell-expressed recombinant PEGylated uricase for the treatment of severe gout; PRX–119, a plant cell-expressed long action DNase I for the treatment of NETs–related diseases; and others. Protalix has partnered with Chiesi Farmaceutici S.p.A., both in the United States and outside the United States, for the development and commercialization of pegunigalsidase alfa.

Investor Contact

Chuck Padala, Managing Director
LifeSci Advisors
+1-646-627-8390
chuck@lifesciadvisors.com

Logo: https://mma.prnewswire.com/media/999479/Protalix_Biotherapeutics_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/protalix-biotherapeutics-to-hold-fiscal-year-2022-financial-and-business-results-conference-call-on-february-27-2023-301751549.html

SOURCE Protalix Biotherapeutics Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When will Protalix BioTherapeutics release its fiscal year 2022 financial results?

Protalix BioTherapeutics will release its fiscal year 2022 financial results on February 27, 2023.

What is the significance of the Protalix conference call on February 27, 2023?

The conference call will discuss the company's financial results and recent corporate developments, providing investors with critical updates.

What products are in Protalix's development pipeline?

Protalix's pipeline includes candidates for Fabry disease treatment and severe gout, among others.

What conference ID should be used for the Protalix conference call?

The conference ID for the call is 13736250.